Floatz Rating
B57/100
Confidence
Indicative
Sponsor
University of Florida
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01954290CT.gov Study of Stroke Related Edema Treatments | — | Withdrawn | — | — | — |
NCT01605357CT.gov Hypernatremia for the Prevention and Treatment of Cerebral Edema in Traumatic Brain Injury | — | Withdrawn | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Brain Edema
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Mannitol (this asset) | University of Florida | P2 | B · 57 |
| Sodium Aescinate | The Second Hospital of Hebei Medical University | P4 | BB |
| Dexasone | Jon Pérez Bárcena | P3 | B |
| Conivaptan | Jesse Corry | P2 | B |
| Famotidine | University of Florida | P2 | B |
| Pantoprazole | University of Florida | P2 | B |
| Dextromethorphan | University of Florida | P2 | B |
| Glibenclamide | Remedy Pharmaceuticals, Inc. | P2 | B |
| Diphenhydramine | University of Florida | P2 | CCC |
+5 more in the Brain Edema cohort
Other indications for Mannitol
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Cystic Fibrosis | — | P4 | BB · 69 |
| Traumatic Brain Injury | — | P4 | BB · 65 |
| Anaplastic Astrocytoma | — | P2 | B · 57 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Mannitol in Brain Edema. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/mannitol-brain-edema
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →